# JY231

Source: https://onco.cc/drugs/jy231/  
OnCo record `jy231` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JY231 is an experimental in vivo CAR-T therapy from Genocury Biotech, in early studies for B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukaemia.

## Summary

JY231 is an in vivo CAR-T (an infusion that makes CAR-T cells inside the body) from Genocury Biotech. The registry says the infusion produces CAR-T cells inside the body; it does not state which protein the CAR recognises. Two investigator-initiated early exploratory studies (NCT06678282, NCT06890065; the registry gives the phase as not applicable) are recruiting. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: JY231 Injection
- Tags: pipeline; ctgov-ingest
- Code: JY231
- Modality: In vivo CAR-T (an infusion that makes CAR-T cells inside the body)
- Mechanism: The registry says the infusion produces CAR-T cells inside the body; it does not state which protein the CAR recognises.

## Sources

- ClinicalTrials.gov NCT06678282: https://clinicaltrials.gov/study/NCT06678282
- ClinicalTrials.gov NCT06890065: https://clinicaltrials.gov/study/NCT06890065

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Genocury Biotech](https://onco.cc/companies/genocury-biotech/)
- trials: [JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia](https://onco.cc/trials/nct06678282/), [JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia](https://onco.cc/trials/nct06890065/)

---
JSON: https://onco.cc/api/v1/entities/jy231.json